Boothbay Fund Management, LLC Satsuma Pharmaceuticals, Inc. Call Options Transaction History

Boothbay Fund Management, LLC

  • $3.37 Billion
  • Q2 2024

Call Options

1 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$4.19 - $7.95 $299,585 - $568,425
71,500 New
71,500 $429,000

About Satsuma Pharmaceuticals, Inc.

STSA Quotes by TradingView
  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email